Diabetes Collaborative Drug Therapy Agreement

07 Déc Diabetes Collaborative Drug Therapy Agreement

We received 55 responses from different sectors, which corresponds to a response rate of 79%. Most physicians had previously worked with a clinical pharmacist (76%) and 60% rated the clinical pharmacist`s performance as extremely important and very important (29.1%; 30.9%). Or maybe. When doctors asked if they had heard of the collaborative drug therapy management agreement or the term CDTM, 67% of respondents had not yet heard it. Most of the responses regarding physicians` awareness of cdTM agreement services themselves were correct. Only 18% selected fake CDTM services. The results showed a higher percentage of physicians who agree with the benefits of the CDTM agreement, as they improve overall patient care, reduce the risk of adverse events or drug-related interactions, and allow clinical pharmacists to be part of patient care; 85.5, 83.6 and 83.6. Physicians who felt that the opportunity to participate or encourage other health professionals to sign cooperation agreements was 76.3 and 74.5 respectively. Because of their specialty, emergency medicine physicians were most likely to have a cdTM agreement and encourage others. On a scale of zero to one hundred years, the average of responses that considered the lack of knowledge of such an agreement as a potential obstacle to the prevention of cdTM agreements was 69 ± 0.30. While the gender barrier was the lowest, with an average of 15. Background: The effect of a pharmacist-managed collaborative drug therapy (CDTA) agreement on the management of diabetes mellitus (MD) in an outpatient setting is assessed.

Current awareness by occupational health care providers in cooperation agreements and barriers to the establishment of cdTM agreements between pharmacists and clinical physicians have been studied. Results: 110 patients in total had an average of 5.7/- 3.9 visits to the pharmacist. An average reduction in HbA (1c) of 0.7% (p < or 0.001, n -93) was achieved, from 8.9% to 8.2% and an average reduction in blood sugar of 26.4 mg/dL (p < or 0.001, n -99). The average cost of hospitalization and hospitalization was significantly higher during the pre-intervention period for patients with DM as a primary or secondary diagnosis ($2434 or $636; p -0.015). In patients with a primary diagnosis of diabetes, the cost of the pre-intervention was higher than the cost of the procedure, but this difference was not significant ($3082 and $696; p – 0.100). A structured investigation was developed as a result of the revision of the CDTM literature. The questions were validated to assess the degree of awareness of the role of clinical pharmacists in making drug therapy management available and to identify the main obstacles to non-cooperation agreements with different specialties.